AU2015329778B2 - Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) - Google Patents

Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) Download PDF

Info

Publication number
AU2015329778B2
AU2015329778B2 AU2015329778A AU2015329778A AU2015329778B2 AU 2015329778 B2 AU2015329778 B2 AU 2015329778B2 AU 2015329778 A AU2015329778 A AU 2015329778A AU 2015329778 A AU2015329778 A AU 2015329778A AU 2015329778 B2 AU2015329778 B2 AU 2015329778B2
Authority
AU
Australia
Prior art keywords
substituted
alkyl
compound
unsubstituted
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015329778A
Other languages
English (en)
Other versions
AU2015329778A1 (en
AU2015329778A8 (en
Inventor
Stuart Cockerill
Jose Miguel Gascon Simorte
Graham Lunn
Neil Mathews
Michael PARADOWSKI
Simon Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51946966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015329778(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2015329778A1 publication Critical patent/AU2015329778A1/en
Publication of AU2015329778A8 publication Critical patent/AU2015329778A8/en
Application granted granted Critical
Publication of AU2015329778B2 publication Critical patent/AU2015329778B2/en
Assigned to PFIZER INC. reassignment PFIZER INC. Request for Assignment Assignors: ReViral Limited
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015329778A 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) Active AU2015329778B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1417707.5 2014-10-07
GBGB1417707.5A GB201417707D0 (en) 2014-10-07 2014-10-07 Pharmaceutical compounds
PCT/GB2015/052920 WO2016055780A1 (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)

Publications (3)

Publication Number Publication Date
AU2015329778A1 AU2015329778A1 (en) 2017-05-04
AU2015329778A8 AU2015329778A8 (en) 2017-05-18
AU2015329778B2 true AU2015329778B2 (en) 2020-04-23

Family

ID=51946966

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015329778A Active AU2015329778B2 (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV)

Country Status (31)

Country Link
US (1) US10106539B2 (enExample)
EP (1) EP3204375B1 (enExample)
JP (1) JP6695334B2 (enExample)
KR (2) KR20230116097A (enExample)
CN (1) CN107108557B (enExample)
AR (1) AR102181A1 (enExample)
AU (1) AU2015329778B2 (enExample)
BR (1) BR112017007311B1 (enExample)
CA (1) CA2963740C (enExample)
CL (1) CL2017000839A1 (enExample)
CO (1) CO2017004603A2 (enExample)
CY (1) CY1121564T1 (enExample)
DK (1) DK3204375T3 (enExample)
ES (1) ES2718976T3 (enExample)
GB (1) GB201417707D0 (enExample)
HR (1) HRP20190808T1 (enExample)
HU (1) HUE043553T2 (enExample)
LT (1) LT3204375T (enExample)
MX (1) MX373233B (enExample)
NZ (1) NZ731323A (enExample)
PE (1) PE20170949A1 (enExample)
PL (1) PL3204375T3 (enExample)
PT (1) PT3204375T (enExample)
RS (1) RS58706B1 (enExample)
RU (1) RU2734248C2 (enExample)
SG (1) SG11201702766YA (enExample)
SI (1) SI3204375T1 (enExample)
SM (1) SMT201900249T1 (enExample)
TR (1) TR201903362T4 (enExample)
TW (1) TWI718107B (enExample)
WO (1) WO2016055780A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197908A1 (zh) * 2015-06-08 2016-12-15 南京明德新药研发股份有限公司 咪唑衍生物及其中间体的制备方法和晶型
WO2018025043A1 (en) 2016-08-04 2018-02-08 ReViral Limited Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection
GB201711704D0 (en) * 2017-07-20 2017-09-06 Reviral Ltd Pharmaceutical compounds
GB201721812D0 (en) * 2017-12-22 2018-02-07 Reviral Ltd Pharmaceutical compounds
CN116077494A (zh) * 2023-01-11 2023-05-09 黑龙江中医药大学 一种治疗呼吸道合胞病毒的药物组合物及其制备方法
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
CN122580320A (zh) 2024-01-16 2026-08-14 辉瑞大药厂 作为n-蛋白抑制剂的苯二氮䓬吡唑甲酰胺类
WO2025248535A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel spirocyclic compounds to treat viral infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068769A1 (en) * 2011-11-10 2013-05-16 Re:Viral Ltd Pharmaceutical compounds
WO2014184163A1 (en) * 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
WO2015022263A1 (en) * 2013-08-12 2015-02-19 F. Hoffmann-La Roche Ag Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
WO2015022301A1 (en) * 2013-08-15 2015-02-19 F. Hoffmann-La Roche Ag Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102863A (en) * 1980-12-16 1982-06-26 Takeda Chem Ind Ltd Spiroindolinone and its preparation
RU2184735C2 (ru) * 1998-01-23 2002-07-10 Санкио Компани, Лимитед Производные спиропиперидина, лекарственное средство, способ профилактики или лечения
EP1418175A1 (en) * 1999-06-28 2004-05-12 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
US7205328B2 (en) * 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
EP1802637B1 (en) 2004-10-13 2008-10-15 Merck & Co., Inc. Cgrp receptor antagonists
US20100278835A1 (en) 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
AU2013334001B2 (en) 2012-10-16 2017-07-20 Janssen Sciences Ireland Uc RSV antiviral compounds
KR20160007629A (ko) * 2013-05-14 2016-01-20 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
KR20160030271A (ko) * 2013-08-12 2016-03-16 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
KR20160030569A (ko) * 2013-08-15 2016-03-18 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 아자-옥소-인돌

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068769A1 (en) * 2011-11-10 2013-05-16 Re:Viral Ltd Pharmaceutical compounds
WO2014184163A1 (en) * 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
WO2015022263A1 (en) * 2013-08-12 2015-02-19 F. Hoffmann-La Roche Ag Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
WO2015022301A1 (en) * 2013-08-15 2015-02-19 F. Hoffmann-La Roche Ag Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Also Published As

Publication number Publication date
AU2015329778A1 (en) 2017-05-04
MX2017004425A (es) 2017-10-11
HRP20190808T1 (hr) 2019-08-23
CA2963740A1 (en) 2016-04-14
JP2017530992A (ja) 2017-10-19
RU2017113026A (ru) 2018-11-13
NZ731323A (en) 2022-09-30
CN107108557B (zh) 2020-11-10
PE20170949A1 (es) 2017-07-13
GB201417707D0 (en) 2014-11-19
HUE043553T2 (hu) 2019-09-30
KR20230116097A (ko) 2023-08-03
CN107108557A (zh) 2017-08-29
BR112017007311B1 (pt) 2022-11-22
DK3204375T3 (en) 2019-04-01
ES2718976T3 (es) 2019-07-05
TR201903362T4 (tr) 2019-04-22
MX373233B (es) 2020-05-08
CY1121564T1 (el) 2020-05-29
KR102561796B1 (ko) 2023-07-31
CL2017000839A1 (es) 2017-10-13
PT3204375T (pt) 2019-04-01
SMT201900249T1 (it) 2019-07-11
CO2017004603A2 (es) 2017-10-31
US20170305908A1 (en) 2017-10-26
KR20170066577A (ko) 2017-06-14
LT3204375T (lt) 2019-05-10
WO2016055780A1 (en) 2016-04-14
RU2734248C2 (ru) 2020-10-13
RU2017113026A3 (enExample) 2019-03-22
EP3204375B1 (en) 2019-02-13
US10106539B2 (en) 2018-10-23
PL3204375T3 (pl) 2019-06-28
CA2963740C (en) 2022-11-29
EP3204375A1 (en) 2017-08-16
AR102181A1 (es) 2017-02-08
TWI718107B (zh) 2021-02-11
AU2015329778A8 (en) 2017-05-18
RS58706B1 (sr) 2019-06-28
TW201625583A (zh) 2016-07-16
BR112017007311A2 (pt) 2017-12-19
JP6695334B2 (ja) 2020-05-20
SG11201702766YA (en) 2017-05-30
SI3204375T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
DK3204375T3 (en) Spiro indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV)
DK2776416T3 (en) Pharmaceutical compounds
US12384764B2 (en) Pharmaceutical compounds
EP4178964A1 (en) Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection
EP4048665A1 (en) Benzodiazepine derivatives for treating a respiratory syncytial virus (rsv) infection
WO2022008912A1 (en) Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection
ES2905650T3 (es) Compuestos farmacéuticos
WO2018025043A1 (en) Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 17 , PAGE(S) 2583 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME REVIRAL LTD , APPLICATION NO. 2015329778, UNDER INID (71) CORRECT THE APPLICANT NAME TO REVIRAL LIMITED

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PFIZER INC.

Free format text: FORMER OWNER(S): REVIRAL LIMITED